Shionogi & Co., Ltd. stock price live, this page displays TYO 4507 stock exchange ... Pro Investing.com May 21, 2025 Shionogi & Co., Ltd. receives Investment Bank Analyst Rating Update Pro ...

OSAKA/TOKYO -- Japanese drugmaker Shionogi said Wednesday that it will acquire Torii Pharmaceutical and other assets from Japan Tobacco in a deal worth around 160 billion yen ($1.1 billion ...

TOKYO, May 7 (Reuters) - Japanese drugmaker Shionogi (4507.T), opens new tab said on Wednesday that it will acquire Torii Pharmaceutical (4551.T), opens new tab, a subsidiary of Japan Tobacco ...

Investors might want to bet on Shionogi & Co., Ltd. Unsponsored ADR (SGIOY), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...

Shionogi has been awarded $375m by the US Department of Health and Human Services (HHS) to develop a long-acting therapeutic aimed at protecting vulnerable populations from Covid-19. The funding ...

OSAKA, Japan, January 16, 2025--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi ...

all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Shionogi & Co. has decided to dissolve its joint ventures with ...

TOKYO (Reuters) - Japan's Shionogi & Co said on Tuesday a global, late-stage study showed its pill-based treatment for COVID-19 was effective in reducing transmission of the disease. Ensitrelvir ...

Michael N. Dudley, PharmD, President and CEO of Qpex Biopharma SAN DIEGO—Shionogi plans to create its first discovery lab in the United States, with a focus on antimicrobial and pandemic ...

The Microsoft Surface Pro 11 could be the most exciting Surface Pro in ages. Not only does it sport an OLED panel, but it also features the new Qualcomm Snapdragon X processors — both of which ...

Tokyo: Japan's Shionogi & Co said on Monday its pill-based treatment for COVID-19 did not meet the primary endpoint of showing a statistically significant reduction of 15 common symptoms of the ...

Shionogi & Co and Maze Therapeutics have announced an exclusive worldwide licensing agreement for an investigational Pompe disease therapy. Estimated to affect about one in 40,000 people in the US, ...